Edition:
United States

AC Immune SA (ACIU.OQ)

ACIU.OQ on NASDAQ Stock Exchange Global Market

11.19USD
14 Dec 2018
Change (% chg)

$-0.51 (-4.36%)
Prev Close
$11.70
Open
$11.68
Day's High
$11.95
Day's Low
$11.10
Volume
38,936
Avg. Vol
26,388
52-wk High
$17.39
52-wk Low
$7.21

Chart for

About

AC Immune SA is a Switzerland-based company engaged in the medical biotechnology sector. It develops treatments for Alzheimer’s and other neurodegenerative diseases, such as Down syndrome, glaucoma and Parkinson's, and focuses on producing therapeutic and diagnostic product candidates, using SupraAntigen and Morphomer technology... (more)

Overall

Beta: --
Market Cap(Mil.): $639.40
Shares Outstanding(Mil.): 56.77
Dividend: --
Yield (%): --

Financials

  ACIU.OQ Industry Sector
P/E (TTM): -- 69.71 34.39
EPS (TTM): -0.69 -- --
ROI: -32.55 9.01 14.96
ROE: -33.72 10.15 16.52

Lilly partners with AC Immune for Alzheimer's treatment

U.S. drugmaker Eli Lilly & Co and AC Immune SA have agreed to jointly develop the Swiss biotech's potential treatment for Alzheimer's disease.

Dec 12 2018

UPDATE 1-Lilly partners with AC Immune for Alzheimer's treatment

Dec 12 U.S. drugmaker Eli Lilly & Co and AC Immune SA have agreed to jointly develop the Swiss biotech's potential treatment for Alzheimer's disease.

Dec 12 2018

Lilly partners with AC Immune for Alzheimer's treatment

Dec 12 Eli Lilly & Co and AC Immune SA have agreed to jointly develop a potential treatment for Alzheimer's disease.

Dec 12 2018

BRIEF-AC Immune Says Co's Selling Shareholder May Sell Up To 18 Mln Common Shares

* AC IMMUNE SAYS CO'S SELLING SHAREHOLDER MAY SELL UP TO 18 MILLION COMMON SHARES Source text: (https://bit.ly/2P0dXMm) Further company coverage:

Aug 24 2018

Earnings vs. Estimates